Compare Match Group Inc (MTCH) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Match Group Inc vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? Match Group Inc trades at $41.48 (market cap $9.53B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.35 (market cap $58.74B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 6.2× Match Group Inc's market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays the higher dividend (3.33%). Which is the better fit depends on your goals — on Pluang, investors hold Match Group Inc for 115 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 0 Days on average.
| MTCH | TAK | |
|---|---|---|
Market Cap | $9.53B | $58.74B |
Volume | 3,228,794 | 3,110,994 |
Sector | Media | Health |
52-Week High | $44.40 | $19.05 |
52-Week Low | $28.90 | $13.23 |
Typical Hold Time | 115 Days | 0 Days |
Enterprise Value | $12.49B | $86.65B |
Dividend Yield | 1.93% | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MTCH trades at $40.86, up 0.59% today, with a bullish technical signal and strong cash flow growth. The company reported a net income margin of 20.17% for 2025, with recent earnings beats in Q4 2025 and Q2 2026. Revenue remains stable at $3.49B, while analyst consensus is a Buy with a $42.29 price target. Positive sentiment is driven by margin expansion and Hinge's growth, though high debt levels and mixed quarterly results present some caution.
The outlook for MTCH is cautiously optimistic, with upside to the consensus target offering ~3.5% potential gain. Strengths include robust profitability, solid cash generation, and product innovation, but risks involve elevated debt, competitive pressures, and reliance on Tinder's turnaround. Investors should weigh strong fundamentals against execution risks in a dynamic dating app market.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Match Group Inc
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
